相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman et al.
CIRCULATION (2022)
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri et al.
DIABETES OBESITY & METABOLISM (2022)
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2022)
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Changes in Kidney Fat upon Dietary-Induced Weight Loss
Manuela Spurny et al.
NUTRIENTS (2022)
Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice
Martin Ho Yin Yeung et al.
FRONTIERS IN PHARMACOLOGY (2022)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Strategies to Treat Obesity in Patients with CKD
Kiran Chintam et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Type 2 diabetes and remission: practical management guided by pathophysiology
Roy Taylor
JOURNAL OF INTERNAL MEDICINE (2021)
The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial
Ilona A. Dekkers et al.
JOURNAL OF RENAL NUTRITION (2021)
Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
Jin-Ju Kim et al.
EBIOMEDICINE (2021)
Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
Zhiqin Zhang et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2021)
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng et al.
HEPATOLOGY INTERNATIONAL (2021)
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Niels Jongs et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Impact of Bariatric Surgery on Adipose Tissue Biology
Oscar Osorio-Conles et al.
JOURNAL OF CLINICAL MEDICINE (2021)
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown et al.
LANCET (2021)
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
Ian J. Neeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
Walter Masson et al.
CELLS (2021)
Renal sinus fat and renal hemodynamics: a cross-sectional analysis
Karlinde A. Spit et al.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Renal and renal sinus fat volumes as quantified by magnetic resonance imaging in subjects with prediabetes, diabetes, and normal glucose tolerance
Mike Notohamiprodjo et al.
PLOS ONE (2020)
Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis
Ke Su et al.
PHARMACOLOGICAL RESEARCH (2020)
Novel Insights and Mechanisms of Lipotoxicity-Driven Insulin Resistance
Benjamin Lair et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin
Peter Rossing et al.
KIDNEY INTERNATIONAL (2019)
Obesity: global epidemiology and pathogenesis
Matthias Blueher
NATURE REVIEWS ENDOCRINOLOGY (2019)
ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes
G. Michelle Ducasa et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Ian J. Neeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Preventing and treating kidney disease in patients with type 2 diabetes
Pierre Delanaye et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Hiddoj L. Heerspink et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Shipra Agrawal et al.
NATURE REVIEWS NEPHROLOGY (2018)
Changes of renal sinus fat and renal parenchymal fat during an 18-month randomized weight loss trial
Hila Zelicha et al.
CLINICAL NUTRITION (2018)
Renal fat fraction and diffusion tensor imaging in patients with early-stage diabetic nephropathy
Yuan-Cheng Wang et al.
EUROPEAN RADIOLOGY (2018)
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
Dong Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
1H-MRS for the assessment of renal triglyceride content in humans at 3T: A primer and reproducibility study
Ilona A. Dekkers et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2018)
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Hans-Joachim Anders et al.
NATURE REVIEWS NEPHROLOGY (2018)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Robert P. Giugliano et al.
CIRCULATION (2018)
Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes
Honglei Guo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
John W. Stanifer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI
Takeshi Yokoo et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2016)
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome The IMPROVE-IT Trial
Sabina A. Murphy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Systemic and renal lipids in kidney disease development and progression
Patricia Wahl et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis
Guido M. Kukuk et al.
EUROPEAN RADIOLOGY (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diabetic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
Hyun Mi Kang et al.
NATURE MEDICINE (2015)
Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
Michal Herman-Edelstein et al.
JOURNAL OF LIPID RESEARCH (2014)
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
Aiko P. J. de Vries et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study
Hiroyuki Takase et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Ezetimibe Ameliorates Early Diabetic Nephropathy in db/db Mice
Yukinori Tamura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2012)
Ezetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria
T. Nakamura et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes A prospective randomized double-blind clinical trial
Piero Ruggenenti et al.
DIABETES CARE (2010)
Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia
Shusuke Yagi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2010)
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner
Tsukasa Nakamura et al.
PHARMACOLOGICAL RESEARCH (2010)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
